A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

Nature Medicine

Volumn 24, Issue 2, 2018, Pages 186-193

  Hyer, Marc L ^a,b   Milhollen, Michael A ^a   Ciavarri, Jeff ^a   Fleming, Paul ^a   Traore, Tary ^a   Sappal, Darshan ^a   Huck, Jessica ^a   Shi, Judy ^a   Gavin, James ^a   Brownell, Jim ^a   Yang, Yu ^a   Stringer, Bradley ^a   Griffin, Robert ^a   Bruzzese, Frank ^a   Soucy, Teresa ^a   Duffy, Jennifer ^a   Rabino, Claudia ^a   Riceberg, Jessica ^a   Hoar, Kara ^a   Lublinsky, Anya ^a   Menon, Saurabh ^a   Sintchak, Michael ^a   Bump, Nancy ^a   Pulukuri, Sai M ^a   Langston, Steve ^a   Tirrell, Stephen ^a   Kuranda, Mike ^a   Veiby, Petter ^a   Newcomb, John ^a   Li, Ping ^a   Wu, Jing Tao ^a   Powe, Josh ^a   DIck, Lawrence R ^a   Greenspan, Paul ^a   Galvin, Katherine ^a   Manfredi, Mark ^a   Claiborne, Chris ^a   Amidon, Benjamin S ^a   Bence, Neil F ^a,c   more..

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b AGIOS PHARMACEUTICALS   (United States)

^c Nurix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LIGASE INHIBITOR; TAK 243; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; IMIDE; MLN7243; NUCLEOSIDE; PROTEASOME; PROTEIN BINDING; SULFONAMIDE; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE PROGRESSION; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; FEMALE; HCT 116 CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WSU-DLCL2 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DNA REPAIR; DRUG EFFECT; DRUG SCREENING; GENETICS; HUMAN; MOLECULAR LIBRARY; NEOPLASM; PATHOLOGY; PHARMACOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; HUMANS; IMIDES; MICE; NEOPLASMS; NUCLEOSIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; SULFONAMIDES; UBIQUITIN; UBIQUITIN-ACTIVATING ENZYMES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85041553883     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4474     Document Type: Article

References (44)

1. Jin, J., Li, X., Gygi, S. P. & Harper, J. W. Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature 447, 1135-1138 (2007).
2. Swatek, K. N. & Komander, D. Ubiquitin modifications. Cell Res. 26, 399-422 (2016).
3. Komander, D. & Rape, M. The ubiquitin code. Annu. Rev. Biochem. 81, 203-229 (2012).
4. Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (2003).
5. Brownell, J. E. et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol. Cell 37, 102-111 (2010).
6. Huang, X. & Dixit, V. M. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 26, 484-498 (2016).
7. Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J. & Brownell, J. E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug Discov. 10, 29-46 (2011).
8. Anderson, D. J. et al. Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis. Cancer Cell 28, 653-665 (2015).
9. Krönke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1in del(5q) MDS. Nature 523, 183-188 (2015).
10. McGrath, J. P., Jentsch, S. & Varshavsky, A. UBA1: an essential yeast gene encoding ubiquitin-activating enzyme. EMBO J. 10, 227-236 (1991).
11. Kulkarni, M. & Smith, H. E. E1 ubiquitin-activating enzyme UBA1 plays multiple roles throughout C. elegans development. PLoS Genet. 4, e1000131 (2008).
12. Misra, M. et al. Dissecting the specificity of adenosyl sulfamate inhibitors targeting the ubiquitin-activating enzyme. Structure 25, 1120-1129 (2017).
13. Amidon, B. S. et al. Indole-substituted pyrrolopyrimidinyl inhibitors of Uba6. US Patent 9593121B2. (2017).
14. Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736 (2009).
15. Hershko, A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ. 12, 1191-1197 (2005).
16. Gu, J. J. et al. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B cell lymphoma preclinical models. Anticancer Drugs 24, 1030-1038 (2013).
17. Milhollen, M. A. et al. Inhibition of NEDD8-activating enzyme induces re-replication and apoptosis in human tumor cells consistent with de-regulating CDT1 turnover. Cancer Res. 71, 3042-3051 (2011).
18. Ulrich, H. D. Ubiquitin and SUMO in DNA repair at a glance. J. Cell Sci. 125, 249-254 (2012).
19. Christianson, J. C. & Ye, Y. Cleaning up in the endoplasmic reticulum: ubiquitin in charge. Nat. Struct. Mol. Biol. 21, 325-335 (2014).
20. Moudry, P. et al. Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage. Cell Cycle 11, 1573-1582 (2012).
21. Ungermannova, D. et al. Identification and mechanistic studies of a novel ubiquitin E1 inhibitor. J. Biomol. Screen. 17, 421-434 (2012).
22. Collins, A. R. The comet assay for DNA damage and repair: principles, applications and limitations. Mol. Biotechnol. 26, 249-261 (2004).
23. Vlachostergios, P. J., Patrikidou, A., Daliani, D. D. & Papandreou, C. N. The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation. J. Cell. Mol. Med. 13 9B, 3019-3031 (2009).
24. Wildey, G. et al. Pharmacogenomic approach to identify drug sensitivity in smallcell-lung cancer. PLoS One 9, e106784 (2014).
25. Wilmott, J. S. et al. BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. Br. J. Cancer 108, 924-931 (2013).
26. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
27. Huang, J. et al. NEDD8 inhibition overcomes CKS1B-induced drug resistance by upregulation of p21 in multiple myeloma. Clin. Cancer Res. 21, 5532-5542 (2015).
28. Milhollen, M. A. et al. Treatment-emergent mutations in NAEconfer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell 21, 388-401 (2012).
29. Yang, Y. et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67, 9472-9481 (2007).
30. Xu, G. W. et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 115, 2251-2259 (2010).
31. Gilbert, L. A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647-661 (2014).
32. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
33. Yau, R. & Rape, M. The increasing complexity of the ubiquitin code. Nat. Cell Biol. 18, 579-586 (2016).
34. Chen, J. J. et al. Mechanistic studies of substrate-assisted inhibition of ubiquitinactivating enzyme by adenosine sulfamate analogs. J. Biol. Chem. 286, 40867-40877 (2011).
35. Gavin, J. M. et al. Mechanistic studies on activation of ubiquitin and di-ubiquitin-like protein, FAT10, by ubiquitin-like-modifier-activating enzyme 6, Uba6. J. Biol. Chem. 287, 15512-15522 (2012).
36. Leslie, A. G. The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 62, 48-57 (2006).
37. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72-82 (2006).
38. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
39. Potterton, E., Briggs, P., Turkenburg, M. & Dodson, E. A graphical user interface to the CCP4 program suite. Acta Crystallogr. D Biol. Crystallogr. 59, 1131-1137 (2003).
40. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
41. Manfredi, M. G. et al. Antitumor activity of MLN8054, an orally active smallmolecule inhibitor of Aurora A kinase. Proc. Natl. Acad. Sci. USA 104, 4106-4111 (2007).
42. Pocock, S. J. & Simon, R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31, 103-115 (1975).
43. Duffey, M. O. et al. Discovery of a potent and orally bioavailable benzolactamderived inhibitor of Polo-like kinase 1 (MLN0905). J. Med. Chem. 55, 197-208 (2012).
44. National Research Council. Guide for the Care and Use of Laboratory Animals 8th edn. (The National Academies Press, 2011).